Publication

Clinical standards for the management of adverse effects during treatment for TB

Abstract
BACKGROUND: Adverse effects (AE) to TB treatment cause morbidity, mortality and treatment interruption. The aim of these clinical standards is to encourage best practise for the diagnosis and management of AE.METHODS: 65/81 invited experts participated in a Delphi process using a 5-point Likert scale to score draft standards.RESULTS: We identified eight clinical standards. Each person commencing treatment for TB should: Standard 1, be counselled regarding AE before and during treatment; Standard 2, be evaluated for factors that might increase AE risk with regular review to actively identify and manage these; Standard 3, when AE occur, carefully assessed and possible allergic or hypersensitivity reactions considered; Standard 4, receive appropriate care to minimise morbidity and mortality associated with AE; Standard 5, be restarted on TB drugs after a serious AE according to a standardised protocol that includes active drug safety monitoring. In addition: Standard 6, healthcare workers should be trained on AE including how to counsel people undertaking TB treatment, as well as active AE monitoring and management; Standard 7, there should be active AE monitoring and reporting for all new TB drugs and regimens; and Standard 8, knowledge gaps identified from active AE monitoring should be systematically addressed through clinical research.CONCLUSION: These standards provide a person-centred, consensus-based approach to minimise the impact of AE during TB treatment.
Author
Singh, K P
Carvalho, A C C
Centis, R
D Ambrosio, L
Migliori, G B
Mpagama, S G
Nguyen, B C
Aarnoutse, R E
Aleksa, A
van Altena, R
Bhavani, P K
Bolhuis, M S
Borisov, S
van T Boveneind-Vrubleuskaya, N
Bruchfeld, J
Caminero, J A
Carvalho, I
Cho, J G
Davies Forsman, L
Dedicoat, M
Dheda, K
Dooley, K
Furin, J
García-García, J M
Garcia-Prats, A
Hesseling, A C
Heysell, S K
Hu, Y
Kim, H Y
Manga, S
Marais, B J
Margineanu, I
Märtson, A-G
Munoz Torrico, M
Nataprawira, H M
Nunes, E
Ong, C W M
Otto-Knapp, R
Palmero, D J
Peloquin, C A
Rendon, A
Rossato Silva, D
Ruslami, R
Saktiawati, A M I
Santoso, P
Schaaf, H S
Seaworth, B
Simonsson, U S H
Singla, R
Skrahina, A
Solovic, I
Srivastava, S
Stocker, S L
Sturkenboom, M G G
Svensson, E M
Tadolini, M
Thomas, T A
Tiberi, S
Trubiano, J
Udwadia, Z F
Verhage, A R
Vu, D H
Akkerman, O W
Alffenaar, J W C
Denholm, J T
Citations
Altmetric:
Date
2023-07
Type
Article
Subject
Communicable diseases, Respiratory medicine
Collections
UHB Infectious Diseases
GEH Day Surgery
Show all metadata
Citation
Singh KP, Carvalho ACC, Centis R, D Ambrosio L, Migliori GB, Mpagama SG, Nguyen BC, Aarnoutse RE, Aleksa A, van Altena R, Bhavani PK, Bolhuis MS, Borisov S, van T Boveneind-Vrubleuskaya N, Bruchfeld J, Caminero JA, Carvalho I, Cho JG, Davies Forsman L, Dedicoat M, Dheda K, Dooley K, Furin J, García-García JM, Garcia-Prats A, Hesseling AC, Heysell SK, Hu Y, Kim HY, Manga S, Marais BJ, Margineanu I, Märtson AG, Munoz Torrico M, Nataprawira HM, Nunes E, Ong CWM, Otto-Knapp R, Palmero DJ, Peloquin CA, Rendon A, Rossato Silva D, Ruslami R, Saktiawati AMI, Santoso P, Schaaf HS, Seaworth B, Simonsson USH, Singla R, Skrahina A, Solovic I, Srivastava S, Stocker SL, Sturkenboom MGG, Svensson EM, Tadolini M, Thomas TA, Tiberi S, Trubiano J, Udwadia ZF, Verhage AR, Vu DH, Akkerman OW, Alffenaar JWC, Denholm JT. Clinical standards for the management of adverse effects during treatment for TB. Int J Tuberc Lung Dis. 2023 Jul 1;27(7):506-519. doi: 10.5588/ijtld.23.0078. PMID: 37353868; PMCID: PMC10321364.
Journal / Source Title
International Journal of Tuberculosis and Lung Disease
DOI
10.5588/ijtld.23.0078
URI
http://hdl.handle.net/20.500.14200/1860
PMID
37353868
Publisher
International Union Against Tuberculosis and Lung Disease
Publisher’s URL
Publisher’s statement
Note / Copyright